GlassScriptPhysician profile
John A Crawford
NPI 1346301538
$11,144.41
in general payments reported to CMS, 2019-2025
39 companies · $1,592 in 2025
The $1,592 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $819 · 2020: $1,353 · 2021: $1,903 · 2022: $1,723 · 2023: $1,817 · 2024: $1,937 · 2025: $1,592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,346.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,346.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,605.34 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $1,720.05 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $1,269.60 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $972.35 | 2019-2025 | Vraylar |
| Novo Nordisk INC | $761.10 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $535.55 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $316.81 | 2019-2025 | Relistor, Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $279.38 | 2019-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $275.19 | 2021-2025 | Caplyta |
| Exact Sciences Corporation | $239.28 | 2023-2025 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $212.22 | 2019-2025 | Austedo Xr |
| Novartis Pharmaceuticals Corporation | $204.15 | 2019-2023 | |
| Allergan, INC. | $186.87 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $130.15 | 2020-2022 | |
| Philips North America LLC | $123.88 | 2020-2024 | (Ak6) Vest Therapy |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $123.63 | 2021-2024 | Yupelri |
| Corcept Therapeutics | $117.84 | 2024 | Korlym |
| Daiichi Sankyo INC. | $108.65 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $107.97 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $97.23 | 2024-2025 | Fanapt |
| Astellas Pharma US INC | $90.74 | 2020-2025 | Veozah |
| Smith+Nephew, INC. | $81.13 | 2019-2024 | Collagenase Santyl |
| Abbott Laboratories | $77.86 | 2021-2025 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $70.93 | 2023-2025 | Rexulti |
| Amarin Pharma, INC. | $63.97 | 2020-2022 | |
| Amgen INC. | $54.18 | 2025 | Repatha |
| Kowa Pharmaceuticals America, INC. | $54.14 | 2021-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $53.14 | 2021-2024 | Eliquis |
| Lundbeck LLC | $29.88 | 2025 | Rexulti |
| Dexcom, INC. | $25.62 | 2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $24.45 | 2023 | Gvoke Hypopen |
| Biohaven Pharmaceutical Holding Company LTD. | $24.18 | 2022 | |
| Inspire Medical Systems, INC. | $21.29 | 2024 | Inspire |
| Paratek Pharmaceuticals, INC. | $18.67 | 2021 | |
| Intra-Sana Laboratories | $17.05 | 2024 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Redhill Biopharma INC. | $14.99 | 2021 | |
| Acorda Therapeutics, INC | $14.17 | 2019 | |
| Phathom Pharmaceuticals, INC. | $11.86 | 2025 | Voquezna |
| Athena Bioscience, LLC | $8.92 | 2023 | Nexiclon Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Crawford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.